v3.25.0.1
Segment and Geographic Area Information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment and Geographic Area Information Segment and Geographic Area Information
AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as Chief Operating Decision Maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by CODM are reported on the Consolidated Statement of Earnings for the years ended December 31, 2024, 2023 and 2022. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included.
Substantially all of AbbVie's pharmaceutical product net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues:
years ended December 31 (in millions)202420232022
Immunology
HumiraUnited States$7,142 $12,160 $18,619 
International1,851 2,244 2,618 
Total$8,993 $14,404 $21,237 
SkyriziUnited States$10,086 $6,753 $4,484 
International1,632 1,010 681 
Total$11,718 $7,763 $5,165 
RinvoqUnited States$4,259 $2,824 $1,794 
International1,712 1,145 728 
Total$5,971 $3,969 $2,522 
Oncology
ImbruvicaUnited States$2,448 $2,665 $3,426 
Collaboration revenues899 931 1,142 
Total$3,347 $3,596 $4,568 
VenclextaUnited States$1,234 $1,087 $1,009 
International1,349 1,201 1,000 
Total$2,583 $2,288 $2,009 
Elahere(a)
United States$477 $— $— 
International2 — — 
Total$479 $— $— 
Epkinly
Collaboration revenues
$118 $28 $— 
International28 3 — 
Total$146 $31 $— 
Aesthetics
Botox Cosmetic
United States$1,682 $1,670 $1,654 
International1,038 1,012 961 
Total$2,720 $2,682 $2,615 
Juvederm Collection
United States$469 $519 $548 
International708 859 880 
Total$1,177 $1,378 $1,428 
Other Aesthetics
United States$1,118 $1,060 $1,122 
International161 174 168 
Total$1,279 $1,234 $1,290 
Neuroscience
Botox Therapeutic
United States$2,718 $2,476 $2,255 
International565 515 464 
Total$3,283 $2,991 $2,719 
Vraylar
United States$3,260 $2,755 $2,037 
International7 4 1 
Total$3,267 $2,759 $2,038 
DuodopaUnited States$96 $97 $95 
International351 371 363 
Total$447 $468 $458 
Ubrelvy
United States$981 $803 $680 
International25 12 — 
Total$1,006 $815 $680 
QuliptaUnited States$628 $405 $158 
International30 3 — 
Total$658 $408 $158 
years ended December 31 (in millions)202420232022
Other Neuroscience
United States$224 $254 $456 
International114 22 19 
Total$338 $276 $475 
Eye Care
OzurdexUnited States$138 $143 $139 
International356 329 289 
Total$494 $472 $428 
Lumigan/Ganfort
United States$187 $173 $242 
International242 259 272 
Total$429 $432 $514 
Alphagan/Combigan
United States$95 $121 $202 
International153 151 144 
Total$248 $272 $346 
Restasis
United States$172 $382 $621 
International52 54 45 
Total$224 $436 $666 
Other Eye Care
United States$472 $433 $399 
International375 370 348 
Total$847 $803 $747 
Other Key Products
MavyretUnited States$595 $659 $755 
International716 771 786 
Total$1,311 $1,430 $1,541 
CreonUnited States$1,383 $1,268 $1,278 
Linzess/Constella
United States$916 $1,073 $1,003 
International38 35 32 
Total$954 $1,108 $1,035 
All other$3,032 $3,035 $4,137 
Total net revenues$56,334 $54,318 $58,054 
(a)Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.
Net revenues to external customers by geographic area, based on product shipment destination, were as follows:
years ended December 31 (in millions)202420232022
United States$43,029 $41,883 $45,713 
Germany1,465 1,266 1,340 
Japan1,122 1,008 956 
Canada1,088 1,076 1,159 
China917 950 912 
France776 780 787 
Spain528 501 506 
United Kingdom522 417 462 
Italy511 484 444 
Brazil464 439 430 
Australia463 472 508 
All other countries5,449 5,042 4,837 
Total net revenues$56,334 $54,318 $58,054 
See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 7), intangible assets impairment expense (Note 7), change in fair value of contingent consideration (Note 11), interest income and expense (Note 3), depreciation expense (Note 2), litigation matters (Note 15), income tax expense (Note 14) and restructuring expense (Note 8).
Long-lived assets, primarily net property and equipment, by geographic area were as follows:
as of December 31 (in millions)20242023
United States
$3,331 $3,139 
Europe1,485 1,433 
All other318 417 
Total long-lived assets$5,134 $4,989